Patients with ER+/HER2+ BC also tend to have a more linear pattern of mortality than those with ER−/HER2+ BC, with relapse often occurring later than that in patients with ER−/HER2+ BC, who tend to relapse earlier [13,14]. The gene discussed is ESR1; the disease is breast cancer.